JP2007529485A5 - - Google Patents

Download PDF

Info

Publication number
JP2007529485A5
JP2007529485A5 JP2007503402A JP2007503402A JP2007529485A5 JP 2007529485 A5 JP2007529485 A5 JP 2007529485A5 JP 2007503402 A JP2007503402 A JP 2007503402A JP 2007503402 A JP2007503402 A JP 2007503402A JP 2007529485 A5 JP2007529485 A5 JP 2007529485A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
formula
nitrogen
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007503402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007529485A (ja
Filing date
Publication date
Priority claimed from GBGB0405933.3A external-priority patent/GB0405933D0/en
Application filed filed Critical
Publication of JP2007529485A publication Critical patent/JP2007529485A/ja
Publication of JP2007529485A5 publication Critical patent/JP2007529485A5/ja
Pending legal-status Critical Current

Links

JP2007503402A 2004-03-16 2005-03-15 ピラゾロ’3,4−b!ピリジン化合物、および4型ホスホジエステラーゼ(pde4)阻害剤としてのその使用 Pending JP2007529485A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0405933.3A GB0405933D0 (en) 2004-03-16 2004-03-16 Compounds
PCT/GB2005/000983 WO2005090348A1 (en) 2004-03-16 2005-03-15 Pyrazolo ’3,4-b! pyridine compounds, and their use as phosphodiesterase type 4 (pde4) inhibitors

Publications (2)

Publication Number Publication Date
JP2007529485A JP2007529485A (ja) 2007-10-25
JP2007529485A5 true JP2007529485A5 (cg-RX-API-DMAC7.html) 2008-05-01

Family

ID=32117818

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007503402A Pending JP2007529485A (ja) 2004-03-16 2005-03-15 ピラゾロ’3,4−b!ピリジン化合物、および4型ホスホジエステラーゼ(pde4)阻害剤としてのその使用

Country Status (5)

Country Link
US (1) US20080021058A1 (cg-RX-API-DMAC7.html)
EP (1) EP1751151A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007529485A (cg-RX-API-DMAC7.html)
GB (1) GB0405933D0 (cg-RX-API-DMAC7.html)
WO (1) WO2005090348A1 (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
RS20050532A (sr) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
WO2005090354A1 (en) 2004-03-16 2005-09-29 Glaxo Group Limited PYRAZOLO[3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS
EA200801997A1 (ru) 2006-04-20 2009-04-28 Глаксо Груп Лимитед Новые соединения
CL2007001829A1 (es) 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
GB0614570D0 (en) * 2006-07-21 2006-08-30 Glaxo Group Ltd Compounds
NZ574533A (en) 2006-08-01 2011-05-27 Glaxo Group Ltd Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
AR070564A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Derivados de 1h-pirazolo[3,4-b]piridin-5-ilo,inhibidores de fosfodiesterasas pde4 y antagonistas de receptores muscarinicos de acetilcolina(machr), utiles en el tratamiento y/o profilaxis de enfermedades respiratorias y alergicas,y composiciones farmaceuticas que los comprenden
CL2009000249A1 (es) 2008-02-06 2009-09-11 Glaxo Group Ltd Compuestos derivados de pirazolo[3,4-b] piridin-butanodiamida; composicion farmaceutica; y su uso en el tratamiento del asma, enfermedad pulmonar obstructiva cronica, rinitis, dermatitis atopica, psoriasis.
UY31637A1 (es) 2008-02-06 2009-08-03 Farmacoforos duales-antagonistas muscarinicos de pde4
EP2280946B1 (en) 2008-06-05 2016-02-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
WO2010016846A1 (en) * 2008-08-08 2010-02-11 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
CA2749403A1 (en) 2009-01-13 2010-09-02 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Itk阻害剤として使用されるピリミジン誘導体
RS53830B1 (sr) 2009-04-30 2015-06-30 Glaxo Group Limited Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
EP2507231A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
WO2011143106A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bi - functional pyrazolopyridine compounds
HRP20151017T1 (hr) 2010-09-08 2015-10-23 Glaxosmithkline Intellectual Property Development Limited Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamida
EP2613781B1 (en) 2010-09-08 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Indazole derivatives for use in the treatment of influenza virus infection
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
KR20160062179A (ko) 2013-10-17 2016-06-01 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 호흡기 질병의 치료를 위한 pi3k 억제제
EP3057588A1 (en) 2013-10-17 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
CN103819339A (zh) * 2014-03-25 2014-05-28 杜承贤 一种有机中间体丁酰基丙二酸二乙酯的制备方法
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
CA3002540C (en) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ, インコーポレイテッド S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3497100A1 (en) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ, インコーポレイテッド S1p1受容体に関連する状態を治療する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60201921T2 (de) * 2001-01-24 2005-10-06 Yung Shin Pharmaceutical Ind. Co., Ltd. Kondensierte Pyrazolverbindungen
BR0314392A (pt) * 2002-09-16 2005-07-12 Glaxo Group Ltd Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds

Similar Documents

Publication Publication Date Title
JP2009510043A5 (cg-RX-API-DMAC7.html)
JP2007529486A5 (cg-RX-API-DMAC7.html)
RU2006131304A (ru) Производные имидазо[1,2-c]пиримидинилуксусной кислоты
JP6021805B2 (ja) 腫瘍治療剤
JP2024543976A5 (cg-RX-API-DMAC7.html)
RU2019118623A (ru) Пирролопиримидины в качестве потенциаторов мвтр
JP2020502103A5 (cg-RX-API-DMAC7.html)
JP2008503585A5 (cg-RX-API-DMAC7.html)
CA2416874A1 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
JP2024508794A5 (cg-RX-API-DMAC7.html)
ATE442367T1 (de) Pyrazolo(3,4-b)pyridinverbindungen und ihre verwendung als phosphodiesterasinhibitoren
US20070270431A1 (en) Preventive and/or Therapeutic Medicine for Rheumatoid Arthritis
RU2011118619A (ru) Аэрозольные фторхинолоны и их применения
RU2014115290A (ru) Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов
RU2015135967A (ru) ТЕТРАГИДРОИМИДАЗО[1,5-d][1,4]ОКСАЗЕПИНОВОЕ ПРОИЗВОДНОЕ
JP2013530179A (ja) 呼吸器合胞体ウイルス(rsv)感染の処置に使用するためのウレイド−ピラゾール誘導体
CA2642922A1 (en) Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
JP2023504415A5 (cg-RX-API-DMAC7.html)
AU2001277751A1 (en) Novel 3-substituted urea derivatives and medicinal use thereof
JP2011524896A5 (cg-RX-API-DMAC7.html)
CA2624621A1 (en) Pyrazine derivatives
RU2012144543A (ru) Производные 3-(гетероариламино)-1,2,3,4-тетрагидро-9н-карбазола и их применение в качестве моддуляторов рецепторов простагландина d2
JP2018508553A5 (cg-RX-API-DMAC7.html)
JP2022105013A (ja) ケモカインの生物活性を中和するためのピリミジノン誘導体およびその使用
JP2017519760A5 (cg-RX-API-DMAC7.html)